ArticleOncotarget2017
Api5 a new cofactor of estrogen receptor alpha involved in breast cancer outcome.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Apoptosis Inhibitor 5: A Multifaceted Regulator of Cell Fate.Biomolecules · 2024Review
- Article
- DeSUMOylation of Apoptosis Inhibitor 5 bymBio · 2021Article
- Interplay between p300 and HDAC1 regulate acetylation and stability of Api5 to regulate cell proliferation.Scientific reports · 2021Article
- Inorganic arsenic influences cell apoptosis by regulating the expression of MEG3 gene.Environmental geochemistry and health · 2021Article
- Interactions between tumor-derived proteins and Toll-like receptors.Experimental & molecular medicine · 2020Review
- Regulation of mRNA export through API5 and nuclear FGF2 interaction.Nucleic acids research · 2020Article
- Roles of eIF3m in the tumorigenesis of triple negative breast cancer.Cancer cell international · 2020Article
- ALG3 Is Activated by Heat Shock Factor 2 and Promotes Breast Cancer Growth.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Api5 (Apoptosis inhibitor 5) is an anti-apoptotic factor that confers resistance to genotoxic stress in human cancer. Api5 is also expressed in endothelial cells and participates to the Estrogen Receptor α (ERα) signaling to promote cell migration. In this study, we found an over expression of Api5 in human breast cancer. Given that we show that high expression of Api5 in breast cancer patients is associated with shorter recurrence free survival, we investigated the relationship between ERα and Api5 at the molecular level. We found that Api5 Nuclear Receptor box (NR box) drives a direct interaction with the C domain of ERα. Furthermore, Api5 participates to gene transcription activation of ERα target genes upon estrogen treatment. Besides, Api5 expression favors tumorigenicity and migration and is necessary for tumor growth
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.